Apolipoprotein E controls the risk and age at onset of Parkinson disease

Neurology

Volumn 62, Issue 11, 2004, Pages 2005-2009

  Li, Y J ^a   Hauser, M A ^a   Scott, W K ^a   Martin, E R ^a   Booze, M W ^a   Qin, X J ^a   Walter, J W ^a   Nance, M A ^b   Hubble, J P ^c   Koller, W C ^d   Pahwa, R ^e   Stern, M B ^f   Hiner, B C ^g   Jankovic, J ^h   Goetz, C G ⁱ   Small, G W ^j   Mastaglia, F ^k   Haines, J L ^l   Pericak Vance, M A ^a   Vance, J M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Struthers Parkinson Center   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g MARSHFIELD CLINIC   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ RUSH UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^l VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E;

ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; DNA POLYMORPHISM; FAMILY HISTORY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PARKINSON DISEASE; PEDIGREE ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 2942562810     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000128089.53030.AC     Document Type: Article

References (35)

1. Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA. Progression of parkinsonism and loss of cognitive function in Alzheimer disease. Arch Neurol 2000;57:855-860.
2. Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.
3. Korczyn AD. Dementia in Parkinson's disease. J Neurol 2001;248(suppl 3):III1-4.
4. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol 2001;58:1817-1820.
5. Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002; 70:985-993.
6. Martin ER, Scott WK, Nance MA, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 2001;286:2245-2250.
7. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261(5123):921-923.
8. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-1356.
9. Khan N, Graham E, Dixon P, et al. Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype. Ann Neurol 2001;49:665-668.
10. Eerola J, Launes J, Hellstrom O, Tienari PJ. Apolipoprotein E (APOE), PARKIN and catechol-O-methyltransferase (COMT) genes and susceptibility to sporadic Parkinson's disease in Finland. Neurosci Lett 2002; 330:296-298.
11. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002;79:458-461.
12. Harhangi BS, de Rijk MC, Van Duijn CM, Van Broeckhoven C, Hofman A, Breteler MM. APOE and the risk of PD with or without dementia in a population-based study. Neurology 2000;54:1272-1276.
13. Maraganore DM, Farrer MJ, Hardy JA, McDonnell SK, Schaid DJ, Rocca WA. Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. Mov Disord 2000;15:714-719.
14. Zareparsi S, Camicioli R, Sexton G, et al. Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet 2002;107: 156-161.
15. Tang G, Xie H, Xu L, Hao Y, Lin D, Ren D. Genetic study of apolipoprotein E gene, alpha-1 antichymotrypsin gene in sporadic Parkinson disease. Am J Med Genet 2002;114:446-449.
16. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001;286:2239-2244.
17. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990;53:245-249.
18. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathological study. Neurology 1992;42:1142-1146.
19. Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T. Reliability of reported age at onset for Parkinson's disease. Mov Disord 2003;18:275-279.
20. Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983;140:734-739.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Fillenbaum GG, Heyman A, Wilkinson WE, Haynes CS. Comparison of two screening tests in Alzheimer's disease. The correlation and reliability of the Mini-Mental State Examination and the modified Blessed test. Arch Neurol 1987;44:924-927.
23. Zillmer EA, Fowler PC, Gutnick HN, Becker E. Comparison of two cognitive bedside screening instruments in nursing home residents: a factor analytic study. J Gerontol 1990;45:69-74.
24. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31: 545-548.
25. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology 1991;41:168-173.
26. Zaykin D, Zhivotovsky L, Weir BS. Exact tests for association between alleles at arbitrary numbers of loci. Genetica 1995;96:169-178.
27. Martin ER, Monks SA, Warren LL, Kaplan NL. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am J Hum Genet 2000;67:146-154.
28. Martin ER, Bass MP, Kaplan NL. Correcting for a potential bias in the pedigree disequilibrium test. Am J Hum Genet 2001;68:1065-1067.
29. Martin ER, Bass MP, Gilbert JR, Pericak-Vance MA, Hauser ER. A genotype-based association test for general pedigrees: the genotype-PDT. Genet Epidemiol 2003;25:203-213.
30. Monks SA, Kaplan NL. Removing the sampling restrictions from family-based tests of association for a quantitative-trait locus. Am J Hum Genet 2000;66:576-592.
31. Abecasis GR, Cardon LR, Cookson WO. A general test of association for quantitative traits in nuclear families. Am J Hum Genet 2000;66:279-292.
32. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet 1994;7:180-184.
33. Schmidt S, Allen IC, Lincoln RR, et al. The role of promoter polymorphisms in the APOE gene in progression of multiple sclerosis (MS). Am J Hum Genet 2002;71(suppl):A1874.
34. Li YJ, Pericak-Vance MA, Haines JL, et al. APOE promoter region is associated with age at onset of amyotrophic lateral sclerosis. Am J Hum Genet 2002;71(suppl):A1636.
35. Schmidt S, Klaver C, Saunders A, et al. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Ophthalmic Genet 2002;23:209-223.